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Kaposi Sarcoma (KS) is driven by human herpes virus 8 causing vascular proliferation which is induced by loss of immune 
function most oen due to HIV or immunosuppressants. KS occurs with increased incidence in kidney transplant recipients, but 
rarely is disseminated. We report a 64-year-old male who developed severely disseminated KS 5 months aer ABO-incompatible 
kidney-transplantation. No guidelines for chemotherapy exist in this case and reduced kidney function and impaired immune system 
complicates the use of systemic chemotherapy in kidney transplant recipients. A combination of paclitaxel and gemcitabine followed 
by two days of hemodialysis treatment was chosen since paclitaxel can be given in full dose independently of kidney function and 
gemcitabine is metabolised to 2′,2′-diuorodeoxyuridine which is found to be highly dialysable. e present treatment was well 
tolerated by the patient with one episode of leukopenia and elevated alanine transaminase during treatment which resolved. ere 
were no serious adverse events and the patient obtained a complete remission veried by Positron Emission Tomography CT aer 
ending chemotherapy and at one-year follow up.
1. Introduction
Kaposi Sarcoma (KS) is a viral induced cancer where infection 
with human herpes virus 8 (HHV-8) is considered the etiolog-
ical agent [1]. Loss of immune function most oen due to HIV 
or immunosuppressants impairing T-cell reactivity, increases 
the risk of viral reactivation and KS occurrence [2, 3]. Due to 
an increase in the prevalence of organ transplanted recipients, 
mainly kidney transplanted recipients, and the use of immu-
nosuppressive therapy the risk of iatrogenic KS has increased. 
Among kidney-transplant recipients, a large multicentre study 
found the incidence of KS to be 0.69% during a median fol-
low-up period of 24 months [4]. KS was mainly cutaneous and 
rarely showed visceral involvement with an incidence of 0.6% 
and 0.09%, respectively [4]. A high incidence of KS in kid-
ney-transplant recipients is reported in numerous studies com-
pared with the general population suggesting a role for 
immunosuppression in the development of the disease [5, 6].
For kidney transplant recipients with only cutaneous 
involvement of KS, complete remission has been obtained by 
conversion from cyclosporine to sirolimus [7]. For KS with 
visceral involvement, no case series or treatment guidelines 
exist for kidney transplant recipients. In HIV-related KS, sys-
temic chemotherapy is generally indicated in rapidly progres-
sive or disseminated disease. Liposomal anthracyclines and 
taxanes are proven active drugs in this setting [8].
Systemic chemotherapy in kidneytransplant recipients is 
complicated due to a reduction in renal clearance and altered 
metabolism of drugs. ere is also a high risk of adverse events 
since the immune system is already compromised by immu-
nosuppressive drugs. erefore, the chemotherapies of choice 
should consider the potential risks of unknown renal clearance 
and potential risk of side e£ects as seen for liposomal anthra-
cyclines [8, 9]. Taxanes alone or in combination therapy could 
represent a more manageable alternative in relation to 
decreased renal function [8].
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2. Case Report
A 64-year-old male developed severely disseminated KS ve 
months aer ABO-incompatible kidney-transplantation. e 
patient had end-stage renal disease due to autosomal domi-
nant polycystic kidney disease and was on peritoneal dialysis 
for eight months prior to transplantation. Per protocol, the 
patient was treated with a single dose rituximab (375 mg/m2) 
and intravenous (i.v.) immunoglobulin therapy (IVIG) before 
transplantation and induction therapy was i.v. basiliximab and 
methylprednisolone (MP). Posttransplantation immunosup-
pression consisted of prednisolone, tacrolimus (Tac), and 
mycophenolatemofetil (MMF). One week aer transplanta-
tion, the patient was treated for borderline rejection with three 
days of i.v. MP (250 mg/day). At discharge, serum creatinine 
was 1.6 mg/dl and immunosuppression was tapered in the 
outpatient clinic. Five months aer transplantation, the patient 
developed purple-red elements on the skin of the forehead, 
nose, and penis. Two months aer presentation of skin 
elements, the patient was admitted and enlarged lymph nodes 
in both groins were found. Biopsies from both skin and lymph 
nodes revealed KS with tumour growth through the capsule 
of the lymph node. A Positron Emission Tomography CT 
(PET-CT) revealed pathologically enlarged and metabolically 
active lymph nodes in the mediastinum, le side of the retro-
peritoneum, and both groins as seen in Figure 1(a). e patient 
tested positive for HHV-8 and negative for HIV. Ten cycles of 
paclitaxel (30 mg) and gemcitabine (304 mg) were given on 
days 1 and 8, with hemodialysis performed the following two 
days aer chemotherapy to remove metabolites of gemcit-
abine. Paclitaxel and gemcitabine doses were increased over 
the treatment period to a nal dose of 138 mg (approximately 
80 mg/m2) and 1416 mg (approximately 800 mg/m2), 
respectively. Immunosuppression was initially changed by 
discontinuing MMF and switching from Tac to everolimus 
(Eve). Due to the severity of the disease Eve was also stopped 
and prednisolone 5 mg/day was given as monotherapy. 
roughout the treatment period, the patient had great vari-
ation in creatinine due to infections and urinary tract obstruc-
tion with creatinine ranging between 1.7 and 6.2 mg/dl. 
PET-CT performed aer courses 4 and 6 and 8 showed regres-
sion of all lymph node enlargements and complete remission 
of KS aer course 10. Hemodialysis was discontinued aer 
termination of chemotherapy and the patient then maintained 
a creatinine of 1.6 mg/dl. A PET-CT 15 months later showed 
continuous complete remission.
3. Discussion
Severely disseminated KS in kidney-transplant recipients is a 
rare condition and no clear recommendations on chemotherapy 
treatment exist. is patient had received an ABO-
incompatible kidney-transplant with a protocol including 
rituximab and IVIG, and received furthermore i.v. MP for 
borderline rejection. In line with the historical data indicating 
an association with decreased immune function and KS 
severity, this increased immunosuppressive treatment may 
explain the rapid progression of KS in this patient. First-line 
treatment with liposomal anthracyclines was not chosen due 
to the uncertain pharmacokinetics imposing a high risk of side 
e£ects or insu¨cient treatment if the dose is reduced [9]. A 
combination of paclitaxel and gemcitabine followed by two 
days of hemodialysis treatment was preferred instead due to 
a more favourable pharmacokinetic prole: paclitaxel can be 
given in full dose independently of kidney function and 
(a)
(b) (c)
Figure 1:  (a) PET-CT at baseline showing an enlarged lymph node in the le and right groin measuring 2.7 × 1.9 cm and 1.4 × 1.6 cm, 
respectively, with increased metabolic activity. Enlarged and hypermetabolic lymph nodes were also found in the mediastinum and the le 
side of the retroperitoneum. (b) PET-CT aer course 10 showing lymph nodes in the le groin with normal size and metabolic activity. Rest 
of the PET-CT showed complete remission of other tumour sites. (c) PET-CT aer 15 months at follow up with no signs of relapse.
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gemcitabine is metabolised to 2′,2′-difluorodeoxyuridine 
(dFdU) which is found to be highly dialysable. is makes it 
a safe treatment option when performing hemodialysis aer 
chemotherapy treatment to remove the metabolites [10]. e 
present treatment was well tolerated by the patient: the patient 
had one episode of leukopenia (1.3 × 109) and elevated alanine 
transaminase (maximum of 133 U/L) during treatment which 
resolved. ere were no serious adverse events and the patient 
obtained a complete remission on PET-CT as seen in 
Figure 1(b).
Reduction in immunosuppression remains a key part of 
treatment for KS. One option was to remove the renal gra to 
allow for a complete tapering of immunosuppressive drugs. 
However, since PET-CT revealed early KS regression, the renal 
gra was not removed, but immunosuppression was reduced 
to a minimum of 5 mg of prednisolone; a dose still maintained 
to minimize risk of KS recurrence and without any signs of 
transplant rejection. At 15 months posttreatment follow up, 
the patient is KS recurrence free as shown by PET-CT in Figure 
1(c), doing well (Performance status according to Eastern 
Cooperative Oncology Group = 0) without any treatment 
related adverse events, and has maintained renal gra function 
with creatinine 15 months aer ending treatment at 1.8 mg/dl.
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